BioNTech data link immune response to delay in tumor recurrence
ASCO data show risk of tumor recurrence reduced 92% in patients with immune response to neoantigen vaccine
Phase I data at ASCO from BioNTech and partner Genentech showed a dramatic reduction in the risk of tumor recurrence for patients who mounted an immune response to a personalized neoantigen vaccine.
In collaboration with Memorial Sloan Kettering Cancer Center, the partners presented data at the annual American Society of Clinical Oncology meeting from 16 evaluable patients with resected pancreatic ductal adenocarcinoma (PDAC). Treatment with autogene cevumeran (BNT122, RO7198457), an mRNA-based individualized neoantigen-specific immunotherapy (iNeST) from BioNTech SE (NASDAQ:BNTX), in combination with PD-L1 inhibitor Tecentriq atezolizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and chemotherapy, induced a neoantigen-specific T cell response in 50% of the patients...